 |
217 Diseases |  |
230 Trials |
|
230 Trials |  |
3979 News |  |
| «12...3031323334353637383940...5051» |
- paclitaxel / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Lipoprotein and metabolite responses to physical exercise during adjuvant breast cancer treatment (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_1161;
P=N/A
The results indicate increased HDL particle number- and function, as well as increased triglyceride clearance in the intervention group. Thus, atherogenic alterations in lipoprotein profile may play a role in evaluating breast cancer treatment, and could potentially be biomarkers of importance for breast cancer prognosis and co-morbidity.
- epirubicin / Generic mfg.
Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy-The Cardiac Care Trial pilot data (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_1141;
Female patients with newly-diagnosed invasive breast cancer scheduled to receive adjuvant or neo-adjuvant anthracycline-based (epirubicin) chemotherapy were recruited...More than one third of patients will develop biochemical evidence of chronic myocardial injury with plasma hs-cTnI concentrations above the 99th centile upper reference limit. This injury is most reliably determined from blood sampling performed before rather than during or after each treatment cycle.
- Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche, cyclophosphamide intravenous / Generic mfg.
Efficacy of two kinds of granulocyte colony-stimulating factors to support neoadjuvant dose-dense chemotherapy in primary breast cancer (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_1137;
All of these patients were planned to receive four cycles of ddEC (Epirubicin 100mg/m2 and cyclophosphamide 600 mg/m2 ) with using one of the following rhG-CSF schedules in parallel: 1) filgrastim 200-300?g/d on day 4, 6, 8, 10; 2) pegfilgrastim 6mg on day 2...Age, tumor size, status of axillary lymph nodes, pathological type and baseline of ANC were not correlated with non-febrile neutropenia in patients using short-term filgrastim.Conclusion : Two schedules of rhG-CSF are effective and safe in supporting four cycles of neoadjuvant ddEC. The effects of these two methods were similar in the completion rate of chemotherapy(RDI?85%) and safety(incidence of FN).
- Nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_853;
Recruitment worldwide is expected to begin in November 2019. For further information, please contact Kristen.Letrent@bms.com.
- paclitaxel / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Prognostic and predictive impact of genes and signatures measured with the BC360 panel (Nanostring) in node positive (?pN2a) high risk patients (pts) receiving dose dense (dd) versus standard dosed chemotherapy in an adjuvant randomized trial with a long term follow-up (FU) (Stars at Night Ballroom 3&4 - 3rd Level) - Sep 25, 2019 - Abstract #SABCS2019SABCS_743;
Our data may indicate that markers associated with immune activation are predictive factors for the use of dd therapies. High risk pts with different benefit from CTX may be identified.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, cyclophosphamide intravenous / Generic mfg., Abraxane (albumin-bound paclitaxel) / Otsuka, BMS
Moved to GS3-01 Investigating denosumab as an add-on treatment to neoadjuvant chemotherapy and two different nab-paclitaxel schedules in a 2x2 design in primary breast cancer - First results of the GeparX study (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_661;
Methods GeparX, a phase II study, was planned to randomize 778 patients to NACT+/-denosumab (120mg s.c. q4w for 6 cycles), stratified by lymphocyte predominant BC (?50% vs >50% stromal tumor infiltrating lymphocytes [sTILs]), subtype (HER2-/HR+ vs triple negative (TNBC) vs HER2+), and epirubicin/cyclophosphamide (EC, q2w vs q3w)...Carboplatin was given in TNBC and ABP 980 + pertuzumab (biosimilar substudy) in HER2+ BC...Conclusions The results of the primary endpoints and selected secondary endpoints will be presented at the meeting. Funding: The trial was financially supported by Amgen and Celgene
- Randomized controlled trial of neoadjuvant eribulin mesylate versus paclitaxel in women with operable breast cancer (JONIE-3 Study) (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_649;
Although the pCR rate was lower in ERI-FEC than PAC-FEC as reported at the previous meeting. ERI was more favorable on adverse events than PTX during NAC treatments.
- paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg.
An innovative approach to breast cancer patient engagement through frontline data capture and management using a mobile application for cancer diagnosis, test, and treatment at a non-profit tertiary cancer center in India (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_524;
Using the pilot, we make a case that this type of technology has the ability to transform cancer care for rural and low-resource health centers that are practicing on the frontlines of cancer care. We also demonstrate that it is easy to capture rich patient longitudinal data using this innovative platform.
- cyclophosphamide intravenous / Generic mfg.
Presence of circulating tumor cells in high-risk early breast cancer do not predict site of metastatic lesions - results of the SUCCESS A trial (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_462;
Although the presence of CTCs predicts poor prognosis in early breast cancer, no association of positive CTC status before and after chemotherapy with the site of metastatic disease was found. Therefore, a positive CTC status should trigger routine diagnostic intervention depending on clinical evaluation.
- | sorafenib / Generic mfg.
New P3 trial: TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 24, 2019
P3, N=162, Not yet recruiting, Sponsor: Sun Yat-sen University
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Enrollment open, Metastases: Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer (clinicaltrials.gov) - Sep 24, 2019
P2, N=258, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Therefore, a positive CTC status should trigger routine diagnostic intervention depending on clinical evaluation. Not yet recruiting --> Recruiting
- Perioperative Therapy with Postoperative Chemoradiotherapy in the Critics Gastric Cancer Trial: A Comparison of Elderly Versus Non-Elderly Patients (ASTRO Innovation Hub) - Sep 24, 2019 - Abstract #ASTRO2019ASTRO_4243;
Although less elderly patients started postoperative CRT, this part of the treatment was tolerated similarly in elderly versus non-elderly patients. Hence, age alone should not be the reason to withhold patients from postoperative CRT.
- ifosfamide / generics, epirubicin / generics
Impact of Adjuvant Therapy on Survival in Treatment of Central Nervous System Hemangiopericytoma (ASTRO Innovation Hub) - Sep 24, 2019 - Abstract #ASTRO2019ASTRO_3122;
Our study shows that Complete excision followed by adjuvant therapy in the form of radiation therapy and chemotherapy improves the survival in CNS Hemangiopericytoma. Besides the prognostic factors assessed, there is a need for larger prospective study to improve the treatment outcomes.
- Keytruda (pembrolizumab) / Merck (MSD), paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Keynote-522 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer: Pathologic complete response in key subgroups (Hall 3) - Sep 23, 2019 - Abstract #SABCS2019SABCS_214;
P3
Pts were randomized 2:1 to the experimental and control arms to receive 4 cycles of [pembro (200 mg Q3W) or placebo (normal saline)] + paclitaxel (80 mg/m2 QW) + carboplatin (AUC 5 Q3W or AUC 1.5 QW) in the first 12 weeks, followed by 4 cycles of pembro/placebo + [doxorubicin (60 mg/m2 Q3W) or epirubicin (90 mg/m2 Q3W)] + cyclophosphamide (600 mg/m2 Q3W) in the subsequent 12 weeks prior to surgery (neoadjuvant part). pCR rates in key patient subgroups will be reported.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Abraxane (albumin-bound paclitaxel) / Otsuka, BMS
Investigating denosumab as an add-on treatment to neoadjuvant chemotherapy and two different nab-paclitaxel schedules in a 2x2 design in primary breast cancer - First results of the GeparX study (Hall 3) - Sep 23, 2019 - Abstract #SABCS2019SABCS_212;
Methods GeparX, a phase II study, was planned to randomize 778 patients to NACT+/-denosumab (120mg s.c. q4w for 6 cycles), stratified by lymphocyte predominant BC (≤50% vs >50% stromal tumor infiltrating lymphocytes [sTILs]), subtype (HER2-/HR+ vs triple negative (TNBC) vs HER2+), and epirubicin/cyclophosphamide (EC, q2w vs q3w)...Carboplatin was given in TNBC and ABP 980 + pertuzumab (biosimilar substudy) in HER2+ BC...Conclusions The results of the primary endpoints and selected secondary endpoints will be presented at the meeting. Funding: The trial was financially supported by Amgen and Celgene.
- Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (cbcsg010): An open-label, randomised, multicentre, phase 3 trial (Hall 3) - Sep 23, 2019 - Abstract #SABCS2019SABCS_118;
P3
Safety data were in line with the known capecitabine safety profile and generally comparable between arms. Capecitabine, when administered concomitantly with standard adjuvant taxane/anthracycline chemotherapy, significantly improved DFS rates in TNBC, with no new safety concerns.
- | Trial completion: Phase II Trial for Large ER-Negative Breast Cancers (clinicaltrials.gov) - Sep 23, 2019
P2, N=72, Completed, Sponsor: University of Colorado, Denver
Capecitabine, when administered concomitantly with standard adjuvant taxane/anthracycline chemotherapy, significantly improved DFS rates in TNBC, with no new safety concerns. Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date, Combination therapy: NeoCART: DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (clinicaltrials.gov) - Sep 23, 2019
P2, N=74, Recruiting, Sponsor: Guangdong General Hospital
Active, not recruiting --> Completed Trial completion date: Sep 2019 --> Dec 2019 | Trial primary completion date: Sep 2018 --> Dec 2019
- COMPARISON OF THE EFFICACY AND SAFETY OF CONVENTIONAL TRANSARTERIAL CHEMOEMBOLIZATION COMBINED WITH AND WITHOUT CALLISPHERES DRUGELUTING BEADS EMBOLIZATION FOR THE TREATMENT OF UNRESECTABLE LARGE HEPATOCELLULAR CARCINOMA () - Sep 20, 2019 - Abstract #ILCA2019ILCA_231;
Compared to cTACE treatment, DEB-TACE combined with cTACE treatment significantly increased tumor-response rate at 1 month after treatment of unresectable larger HCC, and have a longer time in TTP, without any significant increase in severe adverse events. However, long-term clinical efficacy and survival benefits need to be further analyzed in future studies.
- | docetaxel / generics, epirubicin / generics
Clinical, Journal: Colored body images reveal the perceived intensity and distribution of pain in women with breast cancer treated with adjuvant taxanes: a prospective multi-method study of pain experiences. (Pubmed Central) - Sep 20, 2019
There is a time window whereby the risk of pain development is at its highest within 24-48 h after receiving taxane chemotherapy. Proper attention to pain evaluation and treatment should be in focus during this time window.
- | AiTan (rivoceranib) / LSK BioPartners
Clinical, Journal: Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review. (Pubmed Central) - Sep 20, 2019
After that, the disease was slightly progressive during apatinib maintenance and then entered into a "stable" state until now. It indicated that apatinib may be a superior choice for advanced ovarian cancer patients, but further prospective studies are needed to optimize the treatment.
- | epirubicin / Generic mfg.
Enrollment closed, Trial primary completion date: STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 19, 2019
P=N/A, N=109, Active, not recruiting, Sponsor: Boston Scientific Corporation
It indicated that apatinib may be a superior choice for advanced ovarian cancer patients, but further prospective studies are needed to optimize the treatment. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Jun 2019
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer (clinicaltrials.gov) - Sep 18, 2019
P2, N=200, Recruiting, Sponsor: Guangdong General Hospital
- | epirubicin / Generic mfg.
Trial completion date, Trial primary completion date: Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus (clinicaltrials.gov) - Sep 18, 2019
P3, N=253, Recruiting, Sponsor: Shanghai Zhongshan Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Jun 2019 Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jan 2019 --> Apr 2020
- | capecitabine / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date: Trial of Neoadjuvant Docetaxel (clinicaltrials.gov) - Sep 18, 2019
P2, N=170, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jan 2019 --> Apr 2020 Trial primary completion date: Sep 2020 --> Dec 2020
- AiTan (rivoceranib) / HLB Bio Group, camrelizumab (INCSHR1210) / Incyte
A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_686;
P1/2
Funding: Has not received any funding. Clinical trial identification: NCT 03839550.
- epirubicin / generics
Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_629;
Our results demonstrated that MLT inactivating the NF-κB pathway and down-regulating the expression of P-gp, ultimately sensitized EPI-mediated growth suppression of DLBCL cells.Legal entity responsible for the study: The second hospital of Dalian medical university. Funding: Has not received any funding.
- zolbetuximab (IMAB362) / Astellas
SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_565;
P2, P3
Fluorouracil (5-FU), folinic acid, and oxaliplatin (mFOLFOX6) is an accepted chemotherapy for first-line treatment of locally advanced/metastatic GC/GEJ...In a randomized phase 2 study (NCT01630083), patients with CLDN18.2+ advanced GC/GEJ treated with zolbetuximab + epirubicin, oxaliplatin, and capecitabine (EOX) showed prolonged survival compared with EOX alone...Funding: Astellas Pharma US, Inc. Clinical trial identification: NCT03504397.
- zolbetuximab (IMAB362) / Astellas
GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_564;
P2, P3
Funding: Astellas Pharma US, Inc. Clinical trial identification: NCT03653507.
- Avastin (bevacizumab) / Roche
Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_403;
P2
Thus, in neoadjuvant treatment of BC the cell-loss metric, which relates sTK1 to tumor volume, has been noticed as a predictor of pathologic response. Here we found that adding certain established tumor markers significantly improved the predictive power of the metric.
- Keytruda (pembrolizumab) / Merck (MSD), paclitaxel / Generic Mfg., cyclophosphamide intravenous / Generic Mfg.
KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_399;
P3
Funding: Funding for this study was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Clinical trial identification: NCT03725059.
- Herceptin (trastuzumab) / Roche, cyclophosphamide intravenous / Generic Mfg., Abraxane (albumin-bound paclitaxel) / Otsuka, BMS
Effect of apparent diffusion coefficient in predicting pathologic responses in patients with breast cancer treated with neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_381;
High Δnab-PTX ADCs in diffusion-weighted breast MRI may be promising findings for the successful prediction of pCR in patients treated with NAC using nab-PTX followed by FEC.Legal entity responsible for the study: The author. Funding: Has not received any funding.
- capecitabine / Generic Mfg., cyclophosphamide intravenous / Generic Mfg.
Effects of immune architecture on response to adjuvant capecitabine in triple negative breast cancer (FinXX trial) (Hall 405) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_333;
P3
However, analysis of RNA extracted from whole tumor sections lacks spatial discrimination. Using the GeoMx platform for the spatially-defined analysis of protein abundance has provided more insights and has defined specific immune features associated with improved outcome.Legal entity responsible for the study: The authors.
- | Rituxan (rituximab) / Roche, Biogen
Clinical, Retrospective data, Journal: Impact of solid tumor history on treatment response and survival of patients with diffuse large B-cell lymphoma (Pubmed Central) - Sep 16, 2019
The 3-year OS were (74.7±9.5) % and (63.5±6.1) % (χ(2)=2.791, P=0.095) , while 3-year PFS were (72.1±8.8) % and (54.3±6.4) % (χ(2)=1.400, P=0.237) in the double cancer group and the control group, respectively. The history of solid tumors didn't affect DLBCL patients' treatment response and short-term survival.
- | cyclophosphamide intravenous / generics
Clinical, Journal: Hydroxytyrosol Supplementation Modifies Plasma Levels of Tissue Inhibitor of Metallopeptidase 1 in Women with Breast Cancer. (Pubmed Central) - Sep 15, 2019
Women with breast cancer were divided into two groups: a group of patients receiving a dietary supplement of HT and a control group of patients receiving placebo. The results showed that the plasma levels of TIMP-1 in the group of patients receiving HT were significantly lower than those levels found in the control group after the epirubicin-cyclophosphamide chemotherapy.
- Keytruda (pembrolizumab) / Merck (MSD), paclitaxel / Generic Mfg.
KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) (Barcelona Auditorium (Hall 2)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_4486;
P3
Neoadjuvant pembro + chemo followed by adjuvant pembro showed a favorable trend in EFS. AEs were consistent with the known safety profiles of each agent.
- Herceptin (trastuzumab) / Roche
Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the HER2-positive subgroup (Valencia Auditorium (Hall 5)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3125;
P3
Long-term results of the HER2+ subpopulation are in line with the other adjuvant TRA trials but less striking probably due to lack of power. Long term cardiac toxicity and second primary cancer rate are similar to what has been reported by others.
- epirubicin / generics
Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2868;
Despite the use of IC distant control remains insufficient and continues to be a challenge in NPC. Besides improving LRC, more effective systemic therapy is needed.
- doxorubicin hydrochloride / generics, cyclophosphamide intravenous / generics, vincristine / generics
Efficacy and toxicity of combination chemotherapy with cyclophosphamide, vincristine and an anthracycline in patients with metastatic extrapulmonary neuroendocrine carcinoma (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2510;
Despite some encouraging responses, PFS was limited and significant toxicities were observed in the majority of patients. Clinical trial identification: The trial was approved by the institutional research ethics committee (approval S-428/2014).
- zolbetuximab (IMAB362) / Astellas
GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2481;
P2, P3
Legal entity responsible for the study: Astellas Pharma, Inc. Funding: Astellas Pharma, Inc.
- docetaxel / generics, epirubicin / generics
A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: A GISCAD trial (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2460;
P3
These results indicate that, on the basis of the planned futility analysis, it is unlikely that low-TOX regimen is able to reach the target of improvement against EOX, both in efficacy/activity and in tolerability. Therefore, if the clinician’s choice is in favour of a triplet (i.e. in aggressive or very symptomatic disease), EOX could remain a standard option.
- Randomised phase II trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma (SEED) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2441;
P2
Also, CTX had a high rate of febrile neutropenia. CTX is not recommended for patients with esophagogastric cancer, except selected patients intolerant of other standard therapies, and then only with G-CSF support.
- Perioperative chemotherapy with docetaxel, oxaliplatin, fluorouracil and leucovorin (FLOT) versus epirubicin, platinum and capecitabine or flourouracil (EOX/ECF) in resectable gastric or gastroesophageal junction adenocarcinoma: Safety and response data from India (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2428;
The patients in both groups are currently on follow up to capture the relapse free survival duration. Legal entity responsible for the study: Tanuj Chawla.
- paclitaxel / Generic Mfg.
Outcome of triple negative inflammatory breast cancers (TNIBC) treated with dose dense neoadjuvant epirubicin cyclophosphmide, prognostic impact of pre and post neoadjuvant chemotherapy (NAC) tumour infiltrating lymphocytes (TIL) and post NAC lymphovascular invasion (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2046;
Delta TIL is a strong prognostic factor associated with DFS. We show that a positive Delta TILis, among others, a strong and independent predictor of DFS: in TNIBC contrary to the results obtained in TN non inflammatory breast cancers, an increase in TIL after chemotherapy is associated with a decrease in DFS.The exact impact of LVI must be further investigated.
- paclitaxel / Generic Mfg., Tecentriq (atezolizumab) / Roche
ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2035;
P3
Legal entity responsible for the study: This trial is sponsored by Roche and conducted in partnership with the Breast International Group, Frontier Science and Technology Research Foundation, Institute Jules Bordet and Alliance Foundation Trials. Funding: Roche.
- doxorubicin hydrochloride / generics, cyclophosphamide intravenous / generics
A nomogram to predict pathologic complete response of neoadjuvant chemotherapy in triple-negative breast cancer based on simple blood indicators (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2019;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- cyclophosphamide intravenous / generics
Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2004;
Negative effect on TNBC could be a chance finding due to low number of patients but the results warrant caution and necessitate further investigation. Legal entity responsible for the study: The authors.
- Herceptin (trastuzumab) / Roche, paclitaxel / Generic Mfg.
Final results of scalp cooling for hair preservation: A single- institution prospective study (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1947;
Legal entity responsible for the study: Saverio Cinieri. Funding: Has not received any funding.
- Herceptin (trastuzumab) / Roche
The clinical impact of adjuvant dose-dense sequential chemotherapy (dds-CT) in patients with high-risk operable breast cancer (BC): Pooled analysis of 6 clinical trials (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1942;
Legal entity responsible for the study: Hellenic Cooperative Oncology Group (HeCOG). Funding: Hellenic Cooperative Oncology Group (HeCOG).
- paclitaxel / Generic Mfg.
Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1941;
P3
32% of pts reached Hb ≥ 11g/dl at 6 wks. FCM treatment was not different than PhCh for anaemia therapy.